Title of article
Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock
Author/Authors
Rawal, H. A. Internal Medicine - University of Illinois at Urbana-Champaign, Urbana, USA , Kocheril, A. G. Department of Cardiovascular Diseases and Clinical Electrophysiology - Christie Clinic, Urbana, USA
Pages
4
From page
1
To page
4
Abstract
Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor
(ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other
classes of heart failure medications and was started on this new medication. On sacubitril/valsartan, he developed cardiogenic
shock. -is led us to reevaluate the use and risks of this medication in the class IV heart failure population.
Keywords
Cardiogenic Shock , Sacubitril , valsartan , heart failure
Journal title
Case Reports in Cardiology
Serial Year
2018
Full Text URL
Record number
2611362
Link To Document